Diabetes Mellitus, Type 1, Fasting Hypoglycemia
Conditions
Keywords
Type 1 diabetes mellitus, Fasting, Ramadan, Glucagon, Mini-dose, Hypoglycemia
Brief summary
This study aimed to develop a new approach for the treatment of fasting induced hypoglycemia during ramadan using mini-dose glucagon.
Detailed description
This study aimed to understand whether subcutaneously-given mini-dose glucagon (MDG) as an alternative to carbohydrate consumption could avert hypoglycemia or treat it effectively in type 1 diabetes patients who choose to fast during Ramadan in observance of their faith. This treatment method could also avert any negative psychological emotions Muslim people with diabetes may experience by ingesting carbohydrates to control hypoglycemia, thereby breaking their fast. Furthermore, it could improve ability to self-manage fasting, which is an important action for their spiritual and overall wellbeing. There will be two phases included in this study: 1. Pre-crossover Phase: Before starting the crossover trial, a pre-crossover phase will conduct to evaluate hypoglycemia eligibility, frequency and compliance. 2. Crossover Trial Phase: The Crossover Trial Phase will include 20 participants and consist of two (2-weeks) periods. Participants who don't develop any hypoglycemic event or failed to complete both periods will be excluded. Participants will be randomized into two groups: 1. Group A in periods one will use MDG and glucose tablets in period two according to the protocol. 2. Group B in periods one will use glucose tablets and MDG in period two according to the protocol. The primary outcome will be the number of treated fasting induced hypoglycemic events.
Interventions
DRUGGlucagon Injection
Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using mini-dose glucagon when their BG in range 40-69 mg/dl according a prescribed protocol.
OTHERGlucose Tablets
Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using glucose tablets when their BG in range 40-69 mg/dl according a prescribed protocol.
Sponsors
Qassim University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a Randomize Crossover study with a pre-crossover phase and a crossover trial phase, which will include a minimum of 20 participants and consist of two (2-weeks) periods.
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
1. Clinical diagnosis of T1DM using daily insulin 2. 18.0 to \< 65.0 years of age with body mass index 20.0 to \<35.0 kg/m2. 3. Having diabetes for ≥2.0 years 4. HbA1c \<8.5% 5. Has a smart phone with access to the internet and welling to upload data during the study period. 6. Welling to wear a devise such as continuous glucose monitor ≥6 days/week. 7. Females, not currently known to be pregnant 8. In good general health as evaluated by investigator based on available clinical data 9. Willing to comply to the protocol requirements for the duration of the study
Exclusion criteria
1. Any history of more than one severe hypoglycemic episode (need assistance by third party) in the past 12 months 2. Any history of more than one episode of diabetic ketoacidosis in the past 12 months 3. Female pregnant or planning to get pregnant. 4. Use of any of the following medications: oral hypoglycemic agents, systemic corticosteroids or beta-blocker, theophylline, beta-adrenergic agonists, 1st generation anticholinergic drugs. 5. History of hypersensitivity to glucagon or severe hypersensitivity reactions (such as angioedema) to any other medications 6. History of uncontrolled hypertension (systolic BP \>160 mmHg or diastolic BP \>100 mmHg) 7. History of seizure disorder. 8. Presence of any of conditions based on judgment of the investigator that could affect or interfere with the response, absorption, metabolism or execration of glucagon. 9. Currently following any kind of weight-loss diet 10. Currently participation in another clinical trials
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in glucose values from baseline to 30 minute | 30 minutes | The change in blood glucose from baseline to 30 minute following treatment of hypoglycemic events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment success from first dose | 60 Minutes | During the first hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will record the events with blood glucose concentration ≥50 mg/dl 15 minute AND ≥70 mg/dl 30 minute after the initial treatment of a hypoglycemic event |
| Mean Glucose Value, during hypoglycemia event by CGM | 60 Minutes | During the first hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will calculate the mean glucose value from CGM data |
| Time in Range, during hypoglycemia event by CGM | 60 Minutes | During the first hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will calculate the percentage of time in range 70-180 mg/dL from CGM data. |
| Time spend below 70 mg/dL, during hypoglycemia event by CGM | 60 Minutes | During the first hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will calculate the percentage of time \<70 mg/dL from CGM data. |
| Minimum Glucose, during hypoglycemia event by CGM | 60 Minutes | During the first two hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will record the minimum glucose value from CGM data. |
| Maximum Glucose, during hypoglycemia event by CGM | 60 Minutes | During the first two hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will record the maximum glucose value from CGM data. |
| Events approached 100 mg/dL or increased by 30 mg/dL | 60 Minutes | During the first hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will record the events approached 100 mg/dL or increased by 30 mg/dL |
| Mean Glucose Value, by CGM | 2 Weeks | During the entire two weeks of intervention/comparator period, the investigators will calculate the mean glucose value from CGM data |
| Time in Range, by CGM | 2 Weeks | During the entire two weeks of intervention/comparator period, the investigators will calculate the percentage of time in range 70-180 mg/dL from CGM data |
| Time spend below 70 mg/dL, by CGM | 2 Weeks | During the entire two weeks of intervention/comparator period, the investigators will calculate the percentage of time \<70 mg/dL from CGM data |
| Time spend above 180 mg/dL, by CGM | 2 Weeks | During the entire two weeks of intervention/comparator period, the investigators will calculate the percentage of time \>180 mg/dL from CGM data |
| Time spend above 250 mg/dL, by CGM | 2 Weeks | During the entire two weeks of intervention/comparator period, the investigators will calculate the percentage of time \>250 mg/dL from CGM data |
| Coefficient of Variation, by CGM | 2 Weeks | During the entire two weeks of intervention/comparator period, the investigators will calculate the Coefficient of Variation from CGM data |
| The proportion of completion of fasts | 2 Weeks | The proportion of completion of fasts following treatment of hypoglycemic events |
Countries
Saudi Arabia
Outcome results
None listed